2010
Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A, Maloney K, Muralidharan A, Ruf B, Blumberg HP, Sanacora G, Lorberg B, Pittman B, Bhagwagar Z. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. The Journal Of Clinical Psychiatry 2010, 72: 744-50. PMID: 21034692, DOI: 10.4088/jcp.09m05659gre.Peer-Reviewed Original ResearchConceptsDepression Rating ScaleRating ScaleMean changeWeek 6Clinical Global Impression-Bipolar Version ScaleBipolar disorderHamilton Depression Rating Scale scoresMontgomery-Åsberg Depression Rating ScalePlacebo-controlled clinical trialDepression Rating Scale scoresHamilton Depression Rating ScaleYoung Mania Rating ScaleAdjunctive levetiracetam therapyLevetiracetam adjunctive therapySecondary efficacy assessmentsBipolar disorder type IPlacebo-controlled trialHamilton Anxiety Rating ScalePrimary efficacy measureSecondary outcome measuresMajor depressive episodeRating Scale scoresMania Rating ScaleShort-term treatmentSignificant differences
2003
Contrasting effects of citalopram and reboxetine on waking salivary cortisol
Harmer C, Bhagwagar Z, Shelley N, Cowen P. Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology 2003, 167: 112-114. PMID: 12605289, DOI: 10.1007/s00213-003-1417-y.Peer-Reviewed Original ResearchConceptsHPA axis activitySalivary cortisolAxis activitySelective noradrenaline re-uptake inhibitorNoradrenaline re-uptake inhibitorSelective serotonin re-uptake inhibitor citalopramConclusionsShort-term treatmentDifferent antidepressant medicationsHPA axis functionEffect of citalopramRe-uptake inhibitorsDouble-blind designShort-term treatmentBasal salivary cortisol levelsDiurnal salivary cortisolSalivary free cortisolSalivary cortisol levelsAntidepressant administrationRationaleAcute administrationReboxetine treatmentAntidepressant medicationAntidepressant treatmentAxis functionHPA axisAdrenal axis